This is a working overview of GLP-1 receptor, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-12-26 and is reviewed periodically as new material appears.
Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its backbone derives from the native glucose-dependent insulinotropic polypeptide sequence, altered at several positions to resist enzymatic cleavage. A fatty diacid group attached through a linker extends plasma residence time by promoting reversible binding to serum albumin. The molecule carries a net negative charge near physiological pH and has a reported molecular weight close to 4813 daltons. These features separate it from shorter incretin analogs and account for its prolonged dosing interval.
Pharmacologically, tirzepatide activates two distinct G protein-coupled receptors: the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Binding at each target triggers cyclic AMP accumulation and downstream signaling in pancreatic beta cells, adipose tissue and the central nervous system. Because the two pathways overlap only partially, the combined effect on insulin secretion, glucagon suppression and appetite signaling differs from that of selective single-receptor compounds. Affinity is not equal across the two targets, and the clinical meaning of that imbalance remains an area of active study.
Clinical research programs have evaluated tirzepatide in adults with type 2 diabetes and in adults with obesity or excess weight. Trials generally reported reductions in glycated hemoglobin and body weight across treatment periods of several months. Since these studies enrolled defined populations under controlled conditions, the findings describe group averages rather than individual outcomes. Open questions include the durability of effects after treatment stops, variation among subgroups, and the long-term consequences of sustained dual receptor stimulation. Published trial summaries should be consulted for exact measurements rather than secondary accounts.
Tirzepatide 是一种由 39 个氨基酸组成的合成肽，分子结构上以 GIP 序列为骨架并引入脂肪酸侧链修饰，使其能够同时与葡萄糖依赖性促胰岛素多肽（GIP）受体和胰高血糖素样肽-1（GLP-1）受体结合。这种双重激动特性使它在同类肽类药物中区别于选择性 GLP-1 受体激动剂。该分子最早由一家制药公司在 2010 年代报道，随后进入糖尿病与体重管理领域的临床研究。
在生理层面，GIP 与 GLP-1 均为肠道内分泌细胞分泌的肠促胰素，进食后参与胰岛素分泌调节与胃排空抑制。Tirzepatide 通过同时激活这两条信号通路，使胰岛素分泌的葡萄糖依赖性增强，并延缓冲胃排空、降低食欲信号。与单一 GLP-1 激动相比，双靶点作用在血糖控制和体重变化上的效应幅度更大，但具体贡献比例仍在研究之中。
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C225H348N48O68 | Includes the 39-residue backbone and the attached fatty diacid |
| Molecular weight | Approximately 4813 Da | Average mass; the monoisotopic value is slightly lower |
| Receptor targets | GIP receptor and GLP-1 receptor | Dual engagement defines the pharmacological class |
| Backbone length | 39 amino acids | Sequence modified from native glucose-dependent insulinotropic polypeptide |
| Albumin interaction | Reversible, mediated by the fatty diacid | Slows renal clearance and lengthens circulation time |
Receptor activation by tirzepatide raises intracellular cyclic AMP through Gs-coupled signalling at both targets. At the GLP-1 receptor the downstream effect includes glucose-dependent insulin release, suppressed glucagon secretion, delayed gastric emptying, and reduced appetite signalling in the hypothalamus. GIP receptor engagement adds insulinotropic activity and appears to influence lipid handling in adipose tissue. Because both receptors are stimulated at the same time, the pharmacological profile differs from that of selective GLP-1 receptor agonists, and the relative contribution of each arm remains an area of active investigation.
Clinical development proceeded through large phase 3 programmes in type 2 diabetes and in obesity or overweight with at least one weight-related comorbidity. Regulatory approvals followed in several jurisdictions for both indications. Weekly subcutaneous dosing reflects an elimination half-life of roughly five days. Open questions include the durability of metabolic effects after treatment stops, long-term cardiovascular and hepatic outcomes beyond completed trials, and whether the dual mechanism confers benefits independent of total receptor occupancy. Published literature continues to expand on these points. Substantial uncertainty remains about interindividual variability in response.
Tirzepatide is a synthetic peptide that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The molecule contains 39 amino acids and features a C20 fatty diacid moiety attached via a linker, which promotes albumin binding and extends its circulating half-life. Its sequence incorporates non-natural amino acids and modifications that reduce susceptibility to degradation by dipeptidyl peptidase-4. This dual receptor activity distinguishes it from selective GLP-1 receptor agonists.
The GIP receptor is expressed in pancreatic islets, adipose tissue, and the central nervous system, while GLP-1 receptors are found in pancreatic islets, the gastrointestinal tract, and the brain. Activation of both receptors can enhance glucose-dependent insulin secretion and reduce glucagon release. The relative contribution of each receptor to the overall pharmacological effect remains an area of ongoing investigation. Preclinical studies suggest that GIP receptor agonism may modulate appetite and energy balance, but the precise mechanisms in humans are not fully established.
In clinical research, tirzepatide has been studied in randomized controlled trials for glycemic control and body weight reduction. These trials typically measure changes in hemoglobin A1c and body weight over periods of several months. The drug is administered by subcutaneous injection, and its pharmacokinetic profile supports once-weekly dosing. Post-marketing surveillance continues to evaluate long-term outcomes and rare adverse events.
Tirzepatide is a synthetic peptide developed as a dual agonist at the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors. Its structure is built on a GIP-derived backbone with non-natural amino acid substitutions and a fatty diacid side chain that promotes albumin binding and slows clearance. That modification supports once-weekly subcutaneous dosing. Registrational trial programs reported reductions in body weight and glycated hemoglobin alongside the drug's glycemic effects.
Both receptors are class B G protein-coupled receptors that signal largely through Gs-mediated cyclic AMP production. Activation within pancreatic islets increases glucose-dependent insulin secretion and suppresses glucagon release when glucose is elevated. Outside the pancreas, signaling in the central nervous system and gut appears to influence appetite and gastric emptying. The relative contribution of each receptor to observed clinical effects remains under investigation, and the two pathways are not simply additive in practice.
Reported outcomes in large trials include dose-dependent weight reduction and improvements in glycemic markers over periods ranging from several months to more than a year. Whether the compound alters long-term cardiovascular or renal outcomes is being examined in dedicated outcome studies, so those questions remain open. Labeling describes gastrointestinal effects such as nausea and diarrhea, which tend to appear during dose escalation. Discontinuation rates and the durability of effects after treatment stops vary across study populations and are still debated.
=== Pharmacokinetics === In vivo O-dealkylation releases NPA, yielding an orally effective, relatively long-acting dopaminergic agent that acts at central dopamine receptors. Evidence for this prodrug behavior includes blockade of MDO-NPA’s behavioral effects and prevention of NPA formation by the microsomal oxidase inhibitor SKF-525A.
Pilot offers treatment for erectile dysfunction, premature ejaculation, hair loss, and weight management. Juniper provides GLP-1 receptor agonist therapy (such as Ozempic, Mounjaro and Wegovy) combined with health coaching for weight management. Software delivers online dermatology consultations and prescription skincare formulations. Kin provides reproductive health services including contraception, fertility support, and pregnancy care. Compound, a men's preventative health program launched in 2024, was paused later that year before relaunching in the UK in 2025. The company reported revenue of A$120.9 million in FY 2024, with 60% generated from international markets.
=== Adventitious routes === It is a by-product in the production of vinylidene chloride. For instance, it can be formed from trichloroethylene. It is also possible to produce dichloroacetylene from trichloroethylene at low concentrations by running the trichloroethylene through nitrogen at 120 °C in the presence of dry potassium hydroxide.
Sources: en.wikipedia.org
The Soviet Union imposed heavy controls on city growth, preventing some cities from reaching their full potential while promoting others. For the entirety of the Soviet Union's existence, the most populous cities were Moscow and Leningrad (both in Russian SFSR), with the third far place taken by Kiev (Ukrainian SSR). At the USSR's inception, the fourth and fifth most populous cities were Kharkov (Ukrainian SSR) and Baku (Azerbaijan SSR), but, by the end of the century, Tashkent (Uzbek SSR), which had assumed the position of capital of Soviet Central Asia, had risen to fourth place. Minsk (Byelorussian SSR) saw rapid growth during the 20th century, rising from the 32nd most populous in the union to the 7th.
Healthcare centres, including clinics, doctor's offices, urgent care centers and ambulatory surgery centers, serve as first point of contact with a health professional and provide outpatient medical, nursing, dental, and other types of care services.
==== 2000s ==== 2000 – First Medical Inc., Amelung GmbH, ARK Scientific 2001 – ISOTEC (produces stable isotopes used in basic research and medical diagnostics) 2004 – Ultrafine (a supplier of contract manufacturing services for drug development), Tetrionics (a producer of high potency and cytotoxic active pharmaceutical ingredients) 2005 – JRH Biosciences, an industrial supplier of cell culture products for the pharmaceutical and biotechnology industries; Proligo Group, a global supplier of genomics research tools 2006 – Beijing Superior Chemicals, Iropharm, Pharmorphix, Advanced Separation Technologies (manufacturer of products for chiral chromatography) 2007 – Epichem acquired to expand capabilities in materials sciences and semiconductor markets; Molecular Medicine BioServices acquired to provide large-scale viral manufacturing capabilities; announced alliance with Sangamo BioSciences to develop zinc finger-based laboratory research reagents 2009 – ChemNavigator 2010 – Cerilliant Corporation, ACE Animals 2011 – Resource Technology Corp, Vetec Quimica Fina 2012 – Research Organics Inc., BioReliance (a toxicology and veterinary diagnostics company); BioReliance had previously been acquired by Invitrogen and subsequently sold to Avista Capital Partners. 2014 – Cell Marque 2015 – Combined with EMD Millipore to make MilliporeSigma.
The complex geometry of ridges on the inner surface of bat ears helps to sharply focus echolocation signals and to passively listen for any other sound produced by the prey. These ridges can be regarded as the acoustic equivalent of a Fresnel lens. Bats can estimate the elevation of their target using the interference patterns from the echoes reflecting from the tragus, a flap of skin in the external ear.
Sources: en.wikipedia.org
== Autologous grafts == Autologous grafts are used to transfer tissue from one site to another on the same body. The use of autologous grafts prevents transplantation rejection reactions. Grafts used for oral reconstruction are preferably taken from the oral cavity itself (such as gingival and palatal grafts). However, their limited availability and small size leads to the use of either skin transplants or intestinal mucosa to be able to cover bigger defects. Other than tissue shortage, donor site morbidity is a common problem that may occur when using autologous grafts. When tissue is obtained from somewhere other than the oral cavity (such as the intestine or skin) there is a risk of the graft not being able to lose its original donor tissue characteristics. For example, skin grafts are often taken from the radial forearm or lateral upper arm when covering more extensive defects. A positive aspect of using skin grafts is the large availability of skin. However, skin grafts differ from oral mucosa in: consistency, color and keratinization pattern. The transplanted skin graft often continues to grow hair in the oral cavity.
Ravenholm is a fictional ghost town in the 2004 first-person shooter game Half-Life 2 created by Valve. It is the setting for the game's sixth chapter, "We Don't Go To Ravenholm...", which follows protagonist Gordon Freeman as he journeys through the area after escaping a Combine attack in order to reach a nearby Resistance outpost. An Eastern European mining town, Ravenholm's residents have turned into hostile zombies due to Combine attacks. The town's sole survivor, Father Grigori, offers his assistance to Freeman throughout the level, culminating in a last stand at the town cemetery. The level received critical praise due to its level design and unexpected usage of horror aspects involving headcrabs and zombies, with some critics calling it one of the most well-designed levels in a Valve game and one of the best first-person shooter levels ever made. Due to its popularity, Valve initially contracted Junction Point Studios to make a prequel featuring the town, a project that later became a spinoff game developed by Arkane Studios that further followed the story of Grigori and his fight against the Combine. However, both projects were ultimately cancelled partway through development.
The Houthis joined the war on 28 March launching a ballistic missile towards Israel while stating that they had launched ballistic missiles targeting "sensitive" military sites in Israel; the missile was intercepted and no casualties were reported. The Houthis subsequently launched a second missile at Eilat. In response, the internationally recognized Yemeni government condemned Iran's "frequent attempts to drag Yemen" into conflict "through its terrorist militias". On the same day, 2,500 US marines from the 31st Marine Expeditionary Unit arrived in the Middle East, expected to be part of US efforts to open the Strait of Hormuz. US Central Command (CENTCOM) stated that it had struck over 11,000 targets in Iran since the beginning of the war. On 28 March, joint US–Israeli airstrikes severely damaged several residential and civilian facilities, including the Iran University of Science and Technology. In response, Iran threatened to attack Israeli and American colleges across the Middle East. Airstrikes also struck a 10,000-cubic-metre (350,000 cu ft) water reservoir in Haftkel, in Khuzestan province. An Iranian missile struck a chemical plant in the Ne'ot Hovav industrial zone, injuring one person and causing fears of a hazardous leak. A convoy of the Iraqi Popular Mobilization Forces was seen entering Khorramshahr in southwestern Iran. Eleven-year-old child soldier Alireza Jafari was killed in an Israeli drone strike "while serving" at a checkpoint on a Tehran highway; Amnesty International called the organized Iranian recruitment of children as young as Jafari a war crime.
Sources: en.wikipedia.org
It is a synthetic peptide that activates both the GIP and GLP-1 receptors, making it a dual agonist. Approved products are given by injection rather than by mouth. It is not a small molecule and does not belong to the older sulfonylurea or thiazolidinedione families.
Engaging two receptors recruits signaling pathways that only partly coincide. This can shift the magnitude of effects on insulin release, glucagon levels and appetite relative to selective agents. Whether the pairing delivers benefits beyond a simple sum of the two is still debated in the literature.
The proportional contribution of each receptor to observed clinical effects has not been fully separated. Long-term consequences of continuous dual stimulation are likewise unclear. Investigators continue to probe these points through laboratory and clinical work.
它属于合成修饰肽，同时激动 GIP 与 GLP-1 两种肠促胰素受体。这类分子通常被称为双重肠促胰素受体激动剂，与选择性 GLP-1 激动剂在靶点范围上不同。